Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.86 and traded as high as $4.25. Cortexyme shares last traded at $3.77, with a volume of 1,153,649 shares traded.
Cortexyme Stock Down 10.7%
The firm has a market cap of $113.67 million, a PE ratio of -1.27 and a beta of 1.40. The business has a 50 day simple moving average of $2.37 and a two-hundred day simple moving average of $1.86.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
See Also
- Five stocks we like better than Cortexyme
- Health Care Stocks Explained: Why You Might Want to Invest
- Why Taiwan Semiconductor’s 6.5% Dip Could Be a Smart Buy
- How to Find Undervalued Stocks
- RTX Surges to Record Highs as Defense Orders Explode
- What is Short Interest? How to Use It
- Smart Money Is Buying Auto Suppliers, Not Car Brands
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
